Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone949-367-9600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$181.28 million
Profitability
Miscellaneous
Employees437
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Glaukos (NYSE:GKOS) Frequently Asked Questions
What is Glaukos' stock symbol?
Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."
How were Glaukos' earnings last quarter?
Glaukos Corp (NYSE:GKOS) posted its quarterly earnings results on Wednesday, August, 7th. The medical instruments supplier reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.03. The medical instruments supplier earned $58.60 million during the quarter, compared to analyst estimates of $56.24 million. Glaukos had a negative net margin of 5.93% and a negative return on equity of 5.77%. Glaukos's revenue for the quarter was up 35.8% on a year-over-year basis. During the same period in the prior year, the business earned ($0.15) EPS. View Glaukos' Earnings History.
When is Glaukos' next earnings date?
What guidance has Glaukos issued on next quarter's earnings?
Glaukos updated its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $226-231 million, compared to the consensus revenue estimate of $230.07 million.
What price target have analysts set for GKOS?
8 analysts have issued 12-month target prices for Glaukos' stock. Their forecasts range from $57.00 to $80.00. On average, they expect Glaukos' stock price to reach $71.3775 in the next year. This suggests a possible upside of 13.4% from the stock's current price. View Analyst Price Targets for Glaukos.
What is the consensus analysts' recommendation for Glaukos?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Glaukos.
What are Wall Street analysts saying about Glaukos stock?
Here are some recent quotes from research analysts about Glaukos stock:
- 1. BTIG Research analysts commented, "We maintain our Neutral rating on GKOS shares following a solid 1Q19 beat. Largely expected, GKOS delivered rev. of $54.0M vs. BTIG/Street est. of $49.7M/$50.2M as iStent inject conversions and OUS strength drove upside while competitive trialing was modest (below mgmt.’s initial expectations). CyPass share gains continue to buoy US results (we est. $9M-$10M/qtr.) Current business execution, market dynamics, and pricing all appear to be in-line to slightly better than originally guided with no material change to pipeline timelines. Against a ~$4M beat, mgmt. moved the lower-end of guidance up $5M (+$2.5M at the midpoint), sticking with a conservative (but optimistic) tone through the balance of the year. Mgmt. remains cautious around an increase in competitive trialing within the US combined with continued OUS challenges in the UK stemming from reimbursement cuts." (5/10/2019)
- 2. According to Zacks Investment Research, "Glaukos outperformed the industry in a year’s time. Moreover, the company issued guidance for 2019. In the past year, Glaukos made significant progress on the regulatory front and commenced the U.S. commercial launch of iStent Inject. Also, it initiated patient enrolment of key U.S. pivotal clinical studies for iDose Travoprost and iStent Infinite. Through continued investment and a new pharmaceutical development agreement with D. Western Therapeutic Institute Glaukos expanded its pharmaceutical capabilities. A strong pipeline is indicative of brighter prospects ahead. Nonetheless, Glaukos faces cutthroat competition in the Medical Devices space. Further, an overtly stringent regulatory-approval process for the iDose platform is concerning. The stock looks a bit expensive at the moment." (4/30/2019)
Has Glaukos been receiving favorable news coverage?
Media stories about GKOS stock have been trending negative on Sunday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Glaukos earned a coverage optimism score of -2.3 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Glaukos.
Are investors shorting Glaukos?
Glaukos saw a increase in short interest in July. As of July 31st, there was short interest totalling 3,770,900 shares, an increase of 16.4% from the June 30th total of 3,239,000 shares. Based on an average daily volume of 440,600 shares, the short-interest ratio is currently 8.6 days. Approximately 11.1% of the shares of the company are sold short. View Glaukos' Current Options Chain.
Who are some of Glaukos' key competitors?
Some companies that are related to Glaukos include ABIOMED (ABMD), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Cantel Medical (CMD), ICU Medical (ICUI), Tandem Diabetes Care (TNDM), NuVasive (NUVA), Nevro (NVRO), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII) and Atrion (ATRI).
What other stocks do shareholders of Glaukos own?
Who are Glaukos' key executives?
Glaukos' management team includes the folowing people:
- Mr. Thomas William Burns, CEO, Pres & Director (Age 58)
- Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)
- Mr. Chris M. Calcaterra, Chief Operating Officer (Age 59)
- Mr. Richard L. Harrison, Advisor (Age 62)
- Dr. Mory Gharib Ph.D., Co-Founder
When did Glaukos IPO?
(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.
Who are Glaukos' major shareholders?
Glaukos' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.72%), Baillie Gifford & Co. (7.76%), Brown Capital Management LLC (7.19%), BlackRock Inc. (6.99%), William Blair Investment Management LLC (6.63%) and Waddell & Reed Financial Inc. (3.24%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos.
Which major investors are selling Glaukos stock?
GKOS stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Novo Holdings A S, Vanguard Group Inc., D. E. Shaw & Co. Inc., Granite Investment Partners LLC, William Blair Investment Management LLC, Invesco Ltd. and Cortina Asset Management LLC. Company insiders that have sold Glaukos company stock in the last year include Chris M Calcaterra, Gilbert H Kliman, Joseph E Gilliam and William J Phd Link. View Insider Buying and Selling for Glaukos.
Which major investors are buying Glaukos stock?
GKOS stock was bought by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Nuveen Asset Management LLC, C WorldWide Group Holding A S, Brown Capital Management LLC, Point72 Asset Management L.P., Waddell & Reed Financial Inc., Renaissance Technologies LLC and BlackRock Inc.. View Insider Buying and Selling for Glaukos.
How do I buy shares of Glaukos?
Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Glaukos' stock price today?
One share of GKOS stock can currently be purchased for approximately $62.94.
How big of a company is Glaukos?
Glaukos has a market capitalization of $2.29 billion and generates $181.28 million in revenue each year. The medical instruments supplier earns $-12,950,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Glaukos employs 437 workers across the globe.View Additional Information About Glaukos.
What is Glaukos' official website?
How can I contact Glaukos?
Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]
MarketBeat Community Rating for Glaukos (NYSE GKOS)
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
